0000000000326273

AUTHOR

M Perini

showing 2 related works from this author

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

When the amnestic mild cognitive impairment disappears: characterisation of the memory profile

2009

BACKGROUND/OBJECTIVES: Subjects affected by mild cognitive impairment (MCI) may improve during the observation period. This is the first study investigating qualitative features of memory deficits in subjects affected by reversible MCI [reversible cognitive impairment (RCI)]. METHODS: Baseline cognitive and memory performances of 18 subjects affected by amnestic MCI who had normalized cognitive performances at follow-ups were compared with those of 76 amnestic MCI subjects who still showed impaired cognitive performances at the 24-month follow-up (MCI) and with those of a group of 87 matched control subjects (normal controls). RESULTS: Compared with normal controls the memory deficit in the…

MalememorianeuropsychologyAudiologyNeuropsychological TestsAlzheimer diseaseMemoryMild cognitive impairmentNeuropsychologyPreclinical dementiadeterioramento cognitivo lieveLong-term memoryCognitive disorderNeuropsychologypreclinical dementiaCognitionGeneral MedicinePsychiatry and Mental healthNeuropsychology and Physiological PsychologyMemory Short-TermDisease ProgressionFemaleSettore MED/26 - Neurologiamedicine.symptomAlzheimer's diseasePsychologymedicine.medical_specialtyCognitive NeuroscienceAmnesiaHumans; Alzheimer Disease; Disease Progression; Aged; Mental Recall; Cognition Disorders; Memory; Memory Short-Term; Recognition (Psychology); Psychomotor Performance; Follow-Up Studies; Neuropsychological Tests; Amnesia; Female; MaleRecognition (Psychology)M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICAbehavioral disciplines and activitiesmild cognitive impairmentAlzheimer DiseaseMemorymental disordersNeuropsychologiamedicineHumansMemory disorderAgedMED/26 - NEUROLOGIARecognition Psychologymedicine.diseaseMCInervous system diseasesShort-TermMental Recallmild cognitive impairment; neuropsychology; memory; preclinical dementia; Alzheimer diseaseAmnesiaMED/09 - MEDICINA INTERNACognition Disordershuman activitiesNeurosciencePsychomotor PerformanceFollow-Up Studies
researchProduct